Tenet Healthcare Corporation (NYSE:THC) Receives Average Rating of “Buy” from Analysts

Shares of Tenet Healthcare Corporation (NYSE:THC) have been given a consensus recommendation of “Buy” by the twenty ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $275.5263.

Several brokerages have weighed in on THC. Morgan Stanley raised their target price on shares of Tenet Healthcare from $254.00 to $274.00 and gave the company an “overweight” rating in a research note on Monday, July 27th. Raymond James Financial reaffirmed an “outperform” rating and set a $285.00 price target on shares of Tenet Healthcare in a research report on Friday, August 14th. Piper Sandler set a $308.00 price objective on Tenet Healthcare in a research report on Monday, July 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenet Healthcare in a research report on Monday, July 27th. Finally, TD Cowen raised their price target on Tenet Healthcare from $233.00 to $263.00 and gave the stock a “buy” rating in a report on Monday, July 27th.

Insider Buying and Selling

In other news, EVP Lisa Y. Foo sold 24,000 shares of Tenet Healthcare stock in a transaction on Monday, August 31st. The shares were sold at an average price of $266.32, for a total transaction of $6,391,680.00. Following the completion of the sale, the executive vice president directly owned 8,053 shares in the company, valued at approximately $2,144,674.96. The trade was a 74.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nadja West sold 1,152 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $258.80, for a total value of $298,137.60. Following the completion of the transaction, the director directly owned 23,653 shares in the company, valued at approximately $6,121,396.40. The trade was a 4.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 131,199 shares of company stock worth $35,065,587 over the last ninety days. Company insiders own 0.97% of the company’s stock.

Institutional Trading of Tenet Healthcare

Several large investors have recently added to or reduced their stakes in THC. Boston Partners raised its stake in shares of Tenet Healthcare by 15.7% in the fourth quarter. Boston Partners now owns 3,642,136 shares of the company’s stock worth $723,804,000 after purchasing an additional 494,581 shares during the last quarter. Norges Bank acquired a new position in Tenet Healthcare in the 4th quarter worth approximately $248,494,000. Allianz Asset Management GmbH lifted its stake in Tenet Healthcare by 78.1% during the 4th quarter. Allianz Asset Management GmbH now owns 868,134 shares of the company’s stock valued at $172,516,000 after acquiring an additional 380,632 shares during the period. Manning & Napier Advisors LLC purchased a new stake in shares of Tenet Healthcare in the 2nd quarter valued at $168,761,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Tenet Healthcare by 57.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 671,700 shares of the company’s stock worth $126,757,000 after acquiring an additional 244,901 shares during the period. Hedge funds and other institutional investors own 95.44% of the company’s stock.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong value and growth rankings: Zacks identified Tenet as a potential undervalued healthcare stock and included it on its Rank #1 “Strong Buy” lists for both value and growth. The ratings reflect favorable earnings estimates, valuation and momentum factors. Tenet Healthcare Is a Top-Ranked Value Stock
• Positive Sentiment: Healthcare demand and operating efficiency: Zacks highlighted THC among hospital operators benefiting from steady demand for care and improved efficiency. The company’s latest reported quarter also exceeded earnings and revenue expectations, while full-year 2026 EPS guidance remains supportive. Zacks Industry Outlook
• Neutral Sentiment: Conifer restructuring: Tenet’s $2.7 billion Conifer breakup reportedly involves 1,037 job cuts. The separation could streamline the portfolio and improve strategic focus, but the workforce reductions create near-term execution and restructuring risks. Tenet’s Conifer Breakup Triggers Job Cuts
• Negative Sentiment: Large director stock sale: Director J. Robert Kerrey sold 12,010 shares for approximately $3.17 million, reducing his ownership by 71.47%. Although modest relative to Tenet’s market capitalization, the sale may weigh on investor sentiment because it represents significant insider selling. J. Robert Kerrey Sells Tenet Healthcare Shares

Tenet Healthcare Price Performance

Shares of THC stock opened at $261.72 on Friday. The stock’s 50-day moving average is $249.50 and its 200 day moving average is $212.95. Tenet Healthcare has a 1-year low of $157.58 and a 1-year high of $283.05. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. The company has a market cap of $21.07 billion, a P/E ratio of 10.09, a PEG ratio of 1.01 and a beta of 1.23.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the previous year, the company posted $4.02 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Research analysts predict that Tenet Healthcare will post 21.04 earnings per share for the current fiscal year.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company that owns and operates acute care hospitals and other healthcare facilities in the United States. Its hospitals provide services including emergency care, surgery, cardiovascular care, orthopedics, oncology, women’s health and other inpatient and outpatient treatments.

Through its ambulatory business, United Surgical Partners International, Tenet operates and manages ambulatory surgery centers and other outpatient facilities.